Psoriasis Trial, Recruiting NCT06387654 Sponsor: University Hospital, Toulouse Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT06387654
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have skin damage that is known or suspected to be caused by your immune system attacking your own body (autoimmune, immune-related, or inflammatory condition)
  • You have a blistering skin disease caused by the immune system, such as pemphigus or pemphigoid
  • You have a systemic autoimmune disease (a condition affecting multiple parts of the body) that also affects the skin, such as lupus, scleroderma, or dermatomyositis
  • You have a form of lupus that mainly affects the skin
  • You have an immune-related skin condition such as psoriasis or eczema
  • Your skin condition was caused or triggered by a medication or medical treatment
  • You are currently receiving, or may soon receive, a newer or innovative treatment such as gene therapy, cell therapy, or certain cancer immunotherapy drugs (confirm with trial site)
  • You are an adult or a child aged 6 or older
  • Your skin condition is suspected (but not yet confirmed) to be related to an immune system problem

Who may not be able to join:

  • Children under 6 years old
  • People who are pregnant or currently breastfeeding
  • People who are under legal protective supervision, such as those with a court-appointed guardian or curator

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chloé BOST, MD, PhD, University Hospital, Toulouse

Phone: 5 61 77 61 44

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 May 2024
Est. completion
1 April 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Building a collection of biological samples and clinical-biological data from patients with autoimmune, dysimmune or auto-inflammatory dermatological disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov